Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Streamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes

Amer M. Zeidan, MBBS, MHS, Adrienne M. Gilligan, PhD, Santosh Gautam, PhD, David L. Grinblatt, MD, Dina Elsouda, Loretta Sullivan, MD MPH, Bhavik J. Pandya, PharmD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136366

Published: 2020

Journal Articles

Real-World Use of FLT3-TKIs in R/R FLT3-M utated AML in the United States

David L. Grinblatt, MD, Bhavik J. Pandya, PharmD, Wei Han, PhD, Loretta Sullivan, MD MPH, Qi Feng, PhD MS, Nancy Hedlund, PhD MBA, RPh

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-136391

Published: 2020

Journal Articles

Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect ® CLL Registry

Inhye E Ahn, MD, Charles Michael Farber, MD PhD, Matthew Davids, MD, David L. Grinblatt, MD, Nicole Lamanna, MD, Anthony R. Mato, MDMSCE, Chadi Nabhan, MD MBA, FACP, Pavel Kiselev, PhD, Arlene S. Swern, PhD, E. Dawn Flick, RPh, MPH, ScD, Shriya Bhushan, PharmD, Kristen Sullivan, MBA, CCRA, Jeff Sharman, MD, Christopher R. Flowers, MD

Blood (2016) 128 (22): 3581.

https://doi.org/10.1182/blood.V128.22.3581.3581

Published: 2016

Journal Articles

Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT ® Myelodysplastic Syndromes (MDS) and AML Disease Registry

Blood (2016) 128 (22): 3548.

https://doi.org/10.1182/blood.V128.22.3548.3548

Published: 2016

Journal Articles

Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the Connect ® CLL Registry

Jeff Sharman, MD, Matthew Davids, MD, Charles Michael Farber, MD PhD, David L. Grinblatt, MD, Neil E. Kay, MD, Nicole Lamanna, MD, Anthony R. Mato, MD, Chadi Nabhan, MD MBA, FACP, Kristen Sullivan, MBA, CCRA, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Christopher R. Flowers, MD

Blood (2016) 128 (22): 5941.

https://doi.org/10.1182/blood.V128.22.5941.5941

Published: 2016

Journal Articles

Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry

Anthony Mato, MD, Chadi Nabhan, MD, Christopher Flowers, MD, Neil E. Kay, MD, Thomas J. Kipps, MD, PhD, David L. Grinblatt, MD, Nicole Lamanna, MD, Mark Kozloff, MD, Kristen Sullivan, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Jeff P. Sharman, MD

Blood (2015) 126 (23): 4483.

https://doi.org/10.1182/blood.V126.23.4483.4483

Published: 2015

Journal Articles

Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL® Cohort Study

Christopher Flowers, MD, Chadi Nabhan, MD, Neil E. Kay, MD, Anthony Mato, MD, Nicole Lamanna, MD, David L. Grinblatt, MD, Thomas J. Kipps, MD, PhD, Mark Kozloff, MD, Kristen Sullivan, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Jeff P. Sharman, MD

Blood (2015) 126 (23): 3284.

https://doi.org/10.1182/blood.V126.23.3284.3284

Published: 2015

Journal Articles

Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL® Registry

Charles M. Farber, MD, Anthony Mato, MD, Chadi Nabhan, MD, Thomas J. Kipps, MD, PhD, Christopher Flowers, MD, Neil E. Kay, MD, Nicole Lamanna, MD, David L. Grinblatt, MD, Mark Kozloff, MD, Mark Weiss, MD, Kristen Sullivan, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Jeff P. Sharman, MD

Blood (2015) 126 (23): 5270.

https://doi.org/10.1182/blood.V126.23.5270.5270

Published: 2015

Journal Articles

Patterns of Care of Aged Chronic Lymphocytic Leukemia Patients in the United States: Systematic Analysis of 457 Patients in the Connect CLL Registry

Chadi Nabhan, MD FACP, Natalie Galanina, MD, Neil E. Kay, MD, Anthony R. Mato, MD, David L. Grinblatt, MD, Thomas J. Kipps, MD, Nicole Lamanna, MD, Mark Weiss, MD, Ian Flinn, Arlene S. Swern, PhD, Thomas Street, Sullivan Kristen, MBA, Christopher R. Flowers, MD

Blood (2014) 124 (21): 4672.

https://doi.org/10.1182/blood.V124.21.4672.4672

Published: 2014

Journal Articles

Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia

Chris L. Pashos, PhD, Christopher R Flowers, MD, Mark Weiss, MD, Nicole Lamanna, MD, Charles M Farber, MD, PhD, Thomas J. Kipps, M.D., Ph.D, Susan Lerner, MS, BA, Neil Kay, MD, Jeff Porte Sharman, MD, David L. Grinblatt, MD, Ian W. Flinn, MD, PhD, Mark Kozloff, MD, Arlene S Swern, PhD, Zeba M. Kahn, Ph.D, Thomas K. Street, RPh, Kristen A Sullivan, MBA, Gale Harding, MA, Michael J Keating, MD

Blood (2011) 118 (21): 2085.

https://doi.org/10.1182/blood.V118.21.2085.2085

Published: 2011

Journal Articles

Variation in Health-Related Quality of Life by ECOG Performance Status and Fatigue Among Patients with Chronic Lymphocytic Leukemia

Chris L. Pashos, PhD, Christopher R Flowers, MD, Mark Weiss, MD, Nicole Lamanna, MD, Charles M Farber, MD, PhD, Thomas J. Kipps, M.D., Ph.D, Susan Lerner, MS, BA, Neil Kay, MD, Jeff Porte Sharman, MD, David L. Grinblatt, MD, Ian W. Flinn, MD, PhD, Mark Kozloff, MD, Arlene S Swern, PhD, Zeba M. Kahn, Ph.D, Thomas K. Street, RPh, Gale Harding, MA, Kristen A Sullivan, MBA, Michael J Keating, MD

Blood (2011) 118 (21): 4591.

https://doi.org/10.1182/blood.V118.21.4591.4591

Published: 2011

Journal Articles

Association of Changes in Transfusion Status with Changes in Health-Related Quality of Life of Real-World Patients with MDS Across Six Months of Treatment with Azacitidine

Chris L. Pashos, PhD, David L. Grinblatt, MD, Mikkael A. Sekeres, MD, MS, Rami S. Komrokji, MD, Mohit Narang, MD, Arlene S Swern, PhD, Thomas K. Street, RPh, Kristen A Sullivan, MBA, Gale Harding, MA, Zeba M. Khan, PhD

Blood (2011) 118 (21): 2796.

https://doi.org/10.1182/blood.V118.21.2796.2796

Published: 2011

Journal Articles

Therapeutic Response to Azacitidine (AZA) In Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled In the AVIDA Registry

Mikkael A. Sekeres, MD, MS, Mohit Narang, MD, Rami S. Komrokji, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, Alan F. List, MD, Thomas K. Street, R.Ph, MBA, Arlene S. Swern, PhD, Kristen A. Sullivan, MBA, David L. Grinblatt, MD

Blood (2010) 116 (21): 2931.

https://doi.org/10.1182/blood.V116.21.2931.2931

Published: 2010

Journal Articles

A Study Comparing Dosing Regimens and Efficacy of Subcutaneous to Intravenous Azacitidine (AZA) for the Treatment of Myelodysplastic Syndromes (MDS).

Mikkael A. Sekeres, MD, MS, Jaroslaw P. Maciejewski, MD, PhD, David W. Donley, David L. Grinblatt, MD, Mohit Narang, MD, James M. Malone, III, MD, Rami S. Komrokji, MD, Alan F List, MD, Julie G. Baker, David A. Sweet, CMR, Kristen A. Sullivan

Blood (2009) 114 (22): 3797.

https://doi.org/10.1182/blood.V114.22.3797.3797

Published: 2009

Journal Articles

Treatment of Patients with Low-Risk Myelodysplastic Syndromes Receiving Azacitidine Who Are Enrolled in AVIDA, a Longitudinal Patient Registry.

David L. Grinblatt, MD, Mohit Narang, MD, James M. Malone, III, MD, David A. Sweet, Tim S. Dunne, Kristen A. Sullivan

Blood (2008) 112 (11): 1646.

https://doi.org/10.1182/blood.V112.11.1646.1646

Published: 2008

Journal Articles

Transfusion Independence in Patients with Hematologic Disorders Receiving Azacitidine Who Are Enrolled in AVIDA, a Longitudinal Patient Registry

David L. Grinblatt, MD, Mohit Narang, MD, James M. Malone, III, MD, David A. Sweet, Tim S. Dunne, Kristen A. Sullivan

Blood (2008) 112 (11): 2683.

https://doi.org/10.1182/blood.V112.11.2683.2683

Published: 2008

Journal Articles

Short Duration Filgrastim (G-CSF) Therapy (2–4 Days) Is Adequate To Maintain Dose Intensity in Hodgkin’s Lymphoma Patients Treated with Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD).

Lynne S. Kaminer, MD, Seema Bavisi, Jessica Lawton, PharmD, William Uhlig, RPh, George Carro, RPh, David L. Grinblatt, MD

Blood (2006) 108 (11): 4691.

https://doi.org/10.1182/blood.V108.11.4691.4691

Published: 2006

Journal Articles

Azacytidine in the Management of Myelodysplastic Syndrome: A Single Institutional Retrospective Review of Responses and Tolerability.

David L. Grinblatt, MD, Seema Bavisi, Jessica Lawton, PharmD, Lynne S. Kaminer, MD

Blood (2006) 108 (11): 4851.

https://doi.org/10.1182/blood.V108.11.4851.4851

Published: 2006

Journal Articles

Prospective Study of Immunomodulation with GM-CSF, IL-2, and Rituximab Following Autologous Stem Cell Transplant (SCT) in Patients with Relapsed Lymphomas.

Sonali M. Smith, MD, David L. Grinblatt, MD, Thomas Gajewski, MD, PhD, Helena Harlin, PhD, Karen Welborne, BS, Kathy Conner, RN, Richard A. Larson, MD, Elizabeth Rich, MD, Olatoyosi Odenike, MD, Todd Zimmerman, MD, Koen van Besien, MD

Blood (2004) 104 (11): 918.

https://doi.org/10.1182/blood.V104.11.918.918

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Streamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes

Real-World Use of FLT3-TKIs in R/R FLT3-M utated AML in the United States

Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect ® CLL Registry

Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT ® Myelodysplastic Syndromes (MDS) and AML Disease Registry

Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the Connect ® CLL Registry

Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry

Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL® Cohort Study

Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL® Registry

Patterns of Care of Aged Chronic Lymphocytic Leukemia Patients in the United States: Systematic Analysis of 457 Patients in the Connect CLL Registry

Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia

Variation in Health-Related Quality of Life by ECOG Performance Status and Fatigue Among Patients with Chronic Lymphocytic Leukemia

Association of Changes in Transfusion Status with Changes in Health-Related Quality of Life of Real-World Patients with MDS Across Six Months of Treatment with Azacitidine

Therapeutic Response to Azacitidine (AZA) In Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled In the AVIDA Registry

A Study Comparing Dosing Regimens and Efficacy of Subcutaneous to Intravenous Azacitidine (AZA) for the Treatment of Myelodysplastic Syndromes (MDS).

Treatment of Patients with Low-Risk Myelodysplastic Syndromes Receiving Azacitidine Who Are Enrolled in AVIDA, a Longitudinal Patient Registry.

Transfusion Independence in Patients with Hematologic Disorders Receiving Azacitidine Who Are Enrolled in AVIDA, a Longitudinal Patient Registry

Short Duration Filgrastim (G-CSF) Therapy (2–4 Days) Is Adequate To Maintain Dose Intensity in Hodgkin’s Lymphoma Patients Treated with Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD).

Azacytidine in the Management of Myelodysplastic Syndrome: A Single Institutional Retrospective Review of Responses and Tolerability.

Prospective Study of Immunomodulation with GM-CSF, IL-2, and Rituximab Following Autologous Stem Cell Transplant (SCT) in Patients with Relapsed Lymphomas.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only